Serum leptin levels in Iranian patients with Parkinson's disease

Mehri Salari; Mahdi Barzegar; Masoud Etemadifar; Omid Mirmosayyeb

Mehri Salari Department of Neurology, School of Medicine, Qom University of Medical Sciences, Qom, Iran
Mahdi Barzegar Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Masoud Etemadifar Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Omid Mirmosayyeb Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Keywords: Parkinson Disease, Leptin, Iran, Parkinsonism

Abstract

Background: Parkinson's disease (PD), the second most prevalent neurodegenerative disorder, has been related with weight loss and energy balance. Some studies showed that leptin might be playing an important role in satiety, energy balance and immune response. The aim of this study was to evaluate serum leptin level in patients with PD and its association with clinical severity.Methods: In this cross-sectional study, 35 patients with PD and 51 healthy controls (HCs), matched for age, sex and body mass index (BMI), were recruited. Serum leptin level was measured and clinical characteristics and demographic data of patients were recorded.Results: The mean age of patients with PD and HCs were 59.80 ± 11.40 and 62.18 ± 11.60 years, respectively. Serum leptin concentration was not statistically different between patients with PD and HCs (21.1 ± 23.1 ng/ml vs 25.9 ± 21.8 ng/ml, P = 0.280). There was no relation between plasma level of leptin and clinical severity of patients with PD.Conclusion: Our findings suggest that serum level of leptin is neither implicated in the pathogenesis of PD, nor decreases as disease progresses.

References

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363(9423): 1783-93.
2. Burch D, Sheerin F. Parkinson's disease. Lancet 2005; 365(9459): 622-7.
3. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol 2006; 5(3): 235-45.
4. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15(Suppl 1): 14-20.
5. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8(5): 464-74.
6. Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK. The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: A longitudinal study. Eur J Neurol 2016; 23(5): 854-60.
7. Morales-Briceno H, Cervantes-Arriaga A, Rodriguez-Violante M, Calleja-Castillo J, Corona T. Overweight is more prevalent in patients with Parkinson's disease. Arq Neuropsiquiatr 2012; 70(11): 843-6.
8. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC. Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc 1995; 95(9): 979-83.
9. Li XM, Yan HJ, Guo YS, Wang D. The role of leptin in central nervous system diseases. Neuroreport 2016; 27(5): 350-5.
10. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002; 967: 379-88.
11. Lorefalt B, Toss G, Granerus AK. Weight loss, body fat mass, and leptin in Parkinson's disease. Mov Disord 2009; 24(6): 885-90.
12. Fiszer U, Michalowska M, Baranowska B, Wolinska-Witort E, Jeske W, Jethon M, et al. Leptin and ghrelin concentrations and weight loss in Parkinson's disease. Acta Neurol Scand 2010; 121(4): 230-6.
13. Evidente VG, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov Disord 2001; 16(5): 924-7.
14. Harvey J. Leptin: A diverse regulator of neuronal function. J Neurochem 2007; 100(2): 307-13.
15. Harvey J. Leptin regulation of neuronal morphology and hippocampal synaptic function. Front Synaptic Neurosci 2013; 5: 3.
16. Harvey J, Shanley LJ, O'Malley D, Irving AJ. Leptin: A potential cognitive enhancer? Biochem Soc Trans 2005; 33(Pt 5): 1029-32.
17. Udagawa J, Hashimoto R, Suzuki H, Hatta T, Sotomaru Y, Hioki K, et al. The role of leptin in the development of the cerebral cortex in mouse embryos. Endocrinology 2006; 147(2): 647-58.
18. Munshi S, Khemka VK, Banerjee K, Chakrabarti S. Clinicotherapeutic potential of leptin in Alzheimer's disease and Parkinson's disease. J Clin Neurosci 2014; 2014: 181325.
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3): 181-4.
20. Rocha NP, Scalzo PL, Barbosa IG, de Sousa MS, Morato IB, Vieira EL, et al. Circulating levels of adipokines in Parkinson's disease. J Neurol Sci 2014; 339(1-2): 64-8.
21. Aziz NA, Pijl H, Frolich M, Roelfsema F, Roos RA. Leptin, adiponectin, and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease. Mov Disord 2011; 26(4): 760-1.
22. Ozdilek B, Kenangil G. Serum leptin concentrations in Turkish Parkinson's disease population. Parkinsons Dis 2014; 2014: 576020.
23. Kenangil G, Ozdilek B. Serum leptin levels and cognition in Parkinson's disease patients. Noro Psikiyatr Ars 2016; 53(3): 241-4.
24. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269(5223): 540-3.
25. Fulda S, Linseisen J, Wolfram G, Himmerich S, Gedrich K, Pollmacher T, et al. Leptin plasma levels in the general population: Influence of age, gender, body weight and medical history. Protein Pept Lett 2010; 17(11): 1436-40.
26. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003; 46(4): 459-69.
27. Roszkowska-Gancarz M, Jonas M, Owczarz M, Kurylowicz A, Polosak J, Franek E, et al. Age-related changes of leptin and leptin receptor variants in healthy elderly and long-lived adults. Geriatr Gerontol Int 2015; 15(3): 365-71.
28. Hellstrom L, Wahrenberg H, Hruska K, Reynisdottir S, Arner P. Mechanisms behind gender differences in circulating leptin levels. J Intern Med 2000; 247(4): 457-62.
29. Soderberg S, Olsson T, Eliasson M, Johnson O, Brismar K, Carlstrom K, et al. A strong association between biologically active testosterone and leptin in non-obese men and women is lost with increasing (central) adiposity. Int J Obes Relat Metab Disord 2001; 25(1): 98-105.
30. Casabiell X, Pineiro V, Peino R, Lage M, Camina J, Gallego R, et al. Gender differences in both spontaneous and stimulated leptin secretion by human omental adipose tissue in vitro: Dexamethasone and estradiol stimulate leptin release in women, but not in men. J Clin Endocrinol Metab 1998; 83(6): 2149-55.
31. Paul RF, Hassan M, Nazar HS, Gillani S, Afzal N, Qayyum I. Effect of body mass index on serum leptin levels. J Ayub Med Coll Abbottabad 2011; 23(3): 40-3.
32. Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82(6): 1687-91.
33. Saleh HA, El-Nwaem MA, El-Bordiny MM, Maqlad HM, El-Mohandes AA, Eldaqaq EM. Serum leptin elevation in obese women with PCOs: A continuing controversy. J Assist Reprod Genet 2004; 21(10): 361-6.
34. Nishiya K, Nishiyama M, Chang A, Shinto A, Hashimoto K. Serum leptin levels in patients with rheumatoid arthritis are correlated with body mass index. Rinsho Byori 2002; 50(5): 524-7.
35. Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005; 64(8): 1195-8.
36. Novakova L, Haluzik M, Jech R, Urgosik D, Ruzicka F, Ruzicka E. Hormonal regulators of food intake and weight gain in Parkinson's disease after subthalamic nucleus stimulation. Neuro Endocrinol Lett 2011; 32(4): 437-41.